Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-16T20:00:37.989Z Has data issue: false hasContentIssue false
  • English
  • Français

Six years experience with acetylcholinesterase inhibitors in a clinical setting

Published online by Cambridge University Press:  16 April 2020

J.A. Saez Fonseca ,
D. Cutinha ,
K.K. Shanker  and
Z. Walker
J.A. Saez Fonseca
Affiliation:
North Essex Mental Health Partnership NHS Trust, Chelmsford, Essex, United Kingdom University College London, London, United Kingdom
D. Cutinha
Affiliation:
North Essex Mental Health Partnership NHS Trust, Chelmsford, Essex, United Kingdom University College London, London, United Kingdom
K.K. Shanker
Affiliation:
Hertfordshire Partnership NHS Trust, St. Albans, Hertfordshire, United Kingdom
Z. Walker
Affiliation:
North Essex Mental Health Partnership NHS Trust, Chelmsford, Essex, United Kingdom University College London, London, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Evidence for acetylcholinesterase inhibitors (ACIs) available consists mainly of trials conducted by pharmaceutical companies. There are substantial differences between participants in clinical trials and patients in normal clinical settings.

Aims:

To evaluate the use of ACIs in a clinical setting.

Methods:

Hospital records of 454 patients prescribed ACIs over a 6-year period were analysed. In our catchment area of 50,000 people over the age of 65 approximately 100 new patients per year received treatment with ACIs.

Results:

The rate of decline on ACIs was less than half of that expected in an untreated population. A significant difference was found between patients with a baseline MMSE scores greater than 20 and those with a score between 10 and 20.

Conclusions:

Our participants were older than in clinical trials and those with significant medical problems and relative contraindications were not excluded. ACIs are as useful in AD as they are in DLB/PDD and there were no differences between donepezil and rivastigmine. A baseline MMSE score of 20-10 might predict better response to treatment.

Type
Poster Session 2: Organic Mental Disorders and Memory and Cognitive Dysfunctions
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S305
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.